The company's ARCUS platform differs from other technologies in the way it cuts, its smaller size, and simpler structure, with capabilities enabling more intended, defined therapeutic outcomes. With $137M in cash as of December 31, 2025, the company is positioned to fund key data milestones through 2028, focusing on clinical validation of two lead programs in 2026.
Cyborg Score Rationale
Precision BioSciences offers high-risk, high-reward potential with key HBV and DMD data catalysts expected in 2026. The company has adequate cash runway and multiple near-term catalysts, but as a clinical-stage biotech, execution risk remains high.
Top Insights
PBGENE-DMD expecting IND clearance in Q1 2026 with initial data from multiple patients expected in 2026
First-in-class gene editing approach for DMD entering the clinic in early 2026, with cash runway through 2028
FUNCTION-DMD study expected to enroll ambulatory DMD patients with mutations in exons 45-55 impacting up to 60% of boys with DMD, with dosing beginning late Q1/early-Q2 2026
Phase 1/2a ELIMINATE-B trial for PBGENE-HBV ongoing across multiple dosing cohorts with data updates expected at medical conferences in 2026
(February 2026) New preclinical study data supporting potential safety and long-term efficacy of PBGENE-DMD selected as poster presentation at 2026 MDA Conference
(January 2026) Company announced strategic priorities for 2026 with upcoming clinical milestones and $137M cash supporting execution through 2028
(December 2025) Analysts highlighted potential proof-of-concept data for HBV cure expected in 2026
Open the full interactive Precision BioSciences, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.